Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT

On June 2, analyst Vikram Purohit from Morgan Stanley maintained a Hold rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) with a price target of $49.

Keep Reading →